Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) affect 150 million people annually. Despite effective antibiotic therapy, 30-50% of patients experience recurrent UTIs. In addition, the growing prevalence of UPEC that are resistant to last-line antibiotic treatments, and more recently to carbapenems and colistin, make UTI a prime example of the antibiotic-resistance crisis and emphasize the need for new approaches to treat and prevent bacterial infections. UPEC strains establish reservoirs in the gut from which they are shed in the faeces, and can colonize the periurethral area or vagina and subsequently ascend through the urethra to the urinary tract, where they cause UTIs. UPEC isolates encode up to 16 distinct chaperone-usher pathway pili, and each pilus type may enable colonization of a habitat in the host or environment. For example, the type 1 pilus adhesin FimH binds mannose on the bladder surface, and mediates colonization of the bladder. However, little is known about the mechanisms underlying UPEC persistence in the gut. Here, using a mouse model, we show that F17-like and type 1 pili promote intestinal colonization and show distinct binding to epithelial cells distributed along colonic crypts. Phylogenomic and structural analyses reveal that F17-like pili are closely related to pilus types carried by intestinal pathogens, but are restricted to extra-intestinal pathogenic E. coli. Moreover, we show that targeting FimH with M4284, a high-affinity inhibitory mannoside, reduces intestinal colonization of genetically diverse UPEC isolates, while simultaneously treating UTI, without notably disrupting the structural configuration of the gut microbiota. By selectively depleting intestinal UPEC reservoirs, mannosides could markedly reduce the rate of UTIs and recurrent UTIs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654549PMC
http://dx.doi.org/10.1038/nature22972DOI Listing

Publication Analysis

Top Keywords

urinary tract
8
recurrent utis
8
upec isolates
8
intestinal colonization
8
upec
7
utis
5
selective depletion
4
depletion uropathogenic
4
uropathogenic coli
4
gut
4

Similar Publications

Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime?

J Antimicrob Chemother

December 2024

Infectious Diseases Unit, CHU de La Réunion, Saint-Pierre, La Réunion, 97410, France.

Introduction: Temocillin is a semi-synthetic β-lactam with a narrow spectrum but high stability against hydrolysis by β-lactamases, including AmpC. Despite its favourable properties, data regarding its clinical value in the treatment of AmpC β-lactamase-producing Enterobacterales (ABPE) infections are scarce. Most recent guidelines do not include temocillin in the therapeutic strategy for ABPE infection.

View Article and Find Full Text PDF

In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous symptoms associated with EV treatment. Currently, the only reported associations of EV with cutaneous symptoms are pre-treatment performance status (PS) and body weight.

View Article and Find Full Text PDF

In calcium stone formers, most stones grow attached to Randall's plaque, which can be identified by measuring the computed tomography (CT) attenuation value of renal papilla. We hypothesized that the CT attenuation value of renal papilla can predict the severity (recurrent or multiple stone former) and recurrence of the stone disease. We retrospectively reviewed the charts of 180 calcium oxalate stone formers who underwent non-contrast CT and 24-hour urine chemistry in our hospital between September 2012 and November 2021.

View Article and Find Full Text PDF

Background: Optimizing outcomes of hospitalized patients anchors on standardizing processes in medical management, interventions to reduce the risk of decompensation, and prompt intervention when a patient decompensates.

Methods: A quality improvement initiative (optimized sepsis and respiratory compromise management, reducing health care-associated infection and medication risk, swift management of the deteriorating patient, feedback on performance, and accountability) was implemented in a multistate health system. The primary outcome was risk-adjusted in-hospital mortality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!